Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lantern Pharma ( (LTRN) ) has shared an announcement.
Lantern Pharma Inc. announced the appointment of Dr. Lee T. Schalop to its Board of Directors on July 24, 2025. Dr. Schalop brings a wealth of experience from his previous roles in the pharmaceutical and financial industries, including co-founding Oncoceutics, Inc. and serving in executive roles until its sale to Chimerix Inc. Additionally, Lantern Pharma’s Board approved an amendment to the company’s By-laws, reducing the quorum requirement for shareholder meetings from a majority to one-third of the shares entitled to vote. This change aims to facilitate smoother decision-making processes within the company.
The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Average Trading Volume: 218,717
Technical Sentiment Signal: Sell
Current Market Cap: $43.25M
For a thorough assessment of LTRN stock, go to TipRanks’ Stock Analysis page.